Charles Schwab Investment Management Inc. Has $82.23 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

Charles Schwab Investment Management Inc. lowered its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 8.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 501,601 shares of the company's stock after selling 45,031 shares during the period. Charles Schwab Investment Management Inc. owned about 0.61% of DaVita worth $82,227,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Transcendent Capital Group LLC purchased a new stake in shares of DaVita during the third quarter worth $25,000. Blue Trust Inc. raised its position in DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company's stock valued at $29,000 after acquiring an additional 78 shares in the last quarter. Family Firm Inc. bought a new stake in DaVita in the second quarter worth approximately $43,000. Versant Capital Management Inc grew its position in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company's stock worth $45,000 after acquiring an additional 155 shares in the last quarter. Finally, Friedenthal Financial acquired a new position in shares of DaVita during the 2nd quarter worth $48,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on DVA shares. UBS Group upped their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. Truist Financial upped their price target on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. Bank of America raised their price objective on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research note on Wednesday, August 7th. Finally, Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, DaVita has an average rating of "Hold" and a consensus price target of $161.80.

DaVita Stock Performance

NYSE DVA opened at $165.71 on Thursday. The company's fifty day moving average is $158.42 and its two-hundred day moving average is $148.87. DaVita Inc. has a 52-week low of $98.26 and a 52-week high of $169.51. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The firm has a market capitalization of $13.59 billion, a price-to-earnings ratio of 17.88, a P/E/G ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the prior year, the firm earned $2.85 earnings per share. The company's revenue was up 4.6% on a year-over-year basis. Equities research analysts forecast that DaVita Inc. will post 9.71 EPS for the current year.

Insider Buying and Selling

In other news, CEO Javier Rodriguez sold 9,881 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $162.85, for a total value of $1,609,120.85. Following the completion of the transaction, the chief executive officer now directly owns 887,835 shares of the company's stock, valued at approximately $144,583,929.75. This represents a 1.10 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.00% of the stock is owned by company insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.